Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JSKN033 |
Synonyms | |
Therapy Description |
Limited information is currently available on JSKN033, a putative antibody-drug conjugate (ADC) targeting ERBB2 (HER2) (Jan 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JSKN033 | JSKN-033|JSKN 033 | HER2 (ERBB2) Antibody 76 HER2 (ERBB2) Antibody-Drug Conjugate 31 | Limited information is currently available on JSKN033, a putative antibody-drug conjugate (ADC) targeting ERBB2 (HER2) (Jan 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06226766 | Phase Ib/II | JSKN033 | JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors | Recruiting | AUS | 0 |